Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

Last updated: April 7, 2025
Sponsor: University Hospital, Clermont-Ferrand
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hemophilia

Treatment

monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease

Clinical Study ID

NCT05641142
RBHP 2022 GROBOST
2022-A00754-39
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with Rendu-Osler disease with an indication of antiplatelet and/oranticoagulant introduced for less than 3 months (inclusion period within 3 months ofexposure)

  • Age > 18 years old

  • Patient able to understand and agree to participate in the study

  • Affiliation to a social security system

Exclusion

Exclusion Criteria:

  • Patient with an indication of antiplatelet and/or anticoagulant but for whomtreatment has not been introduced or introduced for more than 3 months

  • Refusal to participate

  • Pregnant woman or who are breast feeding

  • Patients under maintenance of justice, wardship or legal guardianship

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
Phase:
Study Start date:
April 07, 2023
Estimated Completion Date:
April 30, 2029

Study Description

Currently there are no recommendations on the use of anticoagulant and/or antiplatelet treatment in patients with Rendu-Osler Disease.

The main question this study aims to answer is:

• to better determine which anticoagulant and/or antiplatelet therapy are best tolerated or if they are equivalent in Rendu-Osler disease because this type of treatment is often used in urgent and/or vital situations.

Participants will have a 2-year follow-up with biological monitoring of ferritin and hemoglobin level and ESS (Epistaxis Severity Score) and QoL-HHT (Quality of Life Hereditary Hemorrhagic Telangiectasia) questionnaires.

Connect with a study center

  • CHU d'Angers

    Angers,
    France

    Site Not Available

  • CHU de Bordeaux

    Bordeaux,
    France

    Site Not Available

  • Hôpital Ambroise Paré

    Boulogne-Billancourt,
    France

    Site Not Available

  • CHU de Caen Normandie

    Caen,
    France

    Site Not Available

  • CHU clermont-ferrand

    Clermont-Ferrand,
    France

    Active - Recruiting

  • CHU de Dijon

    Dijon,
    France

    Site Not Available

  • CHRU de Lille

    Lille,
    France

    Site Not Available

  • Hospices Civiles de Lyon

    Lyon,
    France

    Site Not Available

  • Assistance Publique - Hôpitaux de Marseille

    Marseille,
    France

    Site Not Available

  • CHU de Montpellier

    Montpellier,
    France

    Site Not Available

  • CHU de Nancy

    Nancy,
    France

    Site Not Available

  • CHU de Nantes

    Nantes,
    France

    Site Not Available

  • CHU de Nice

    Nice,
    France

    Site Not Available

  • AP-HP - Hôpital Ténon

    Paris,
    France

    Site Not Available

  • CHU de Poitiers

    Poitiers,
    France

    Site Not Available

  • CHU de Rennes

    Rennes,
    France

    Site Not Available

  • CHRU de Strasbourg

    Strasbourg,
    France

    Site Not Available

  • CHU de Toulouse

    Toulouse,
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.